Literature DB >> 30747749

Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.

Velprashanth Venkatesan1, Sourav Khanra, Kamalika Mandal, M B Deepak.   

Abstract

OBJECTIVE: Long-acting depot preparations of antipsychotics are the mainstay of treatment for patients with schizophrenia who show nonadherence to their medications. Olanzapine pamoate is one of the recently approved long-acting depot psychotropic preparations that have shown its efficacy both in clinical trials and in clinical uses against the illness. However, emerging literature indicates toward a cluster of adverse effects known as postinjection delirium/sedation syndrome (PDSS).
METHODS: We here present a case of PDSS in a woman with paranoid schizophrenia. After maintaining well for almost 1½ years, she developed PDSS at her 31st scheduled long-acting olanzapine injection.
RESULTS: Several features of PDSS including its mechanism and course have been discussed.
CONCLUSIONS: More research is necessary to understand the syndrome and the association between PDSS and long-acting olanzapine injection. Clinicians should keep in mind that PDSS may worsen compliance in an index patient and affect the course of the illness.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30747749     DOI: 10.1097/WNF.0000000000000329

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  3 in total

1.  Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital.

Authors:  Sandeep Grover; Himanshu Singla; Subho Chakrabarti; Ajit Avasthi
Journal:  Indian J Psychol Med       Date:  2020-03-09

2.  Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?

Authors:  Carol Paton; Chike I Okocha; Maxine X Patel
Journal:  Ther Adv Psychopharmacol       Date:  2022-02-15

3.  Postinjection delirium/sedation syndrome in a transgender man undergoing hormone therapy.

Authors:  Joshua Gerving; Heather Walser; Anne C Kelly
Journal:  Ment Health Clin       Date:  2022-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.